Lilly's next-gen drug outshines Ozempic on weight loss, blood sugar control in trial

What happened

Eli Lilly said its experimental drug retatrutide beat a 2 mg dose of Novo Nordisk's Ozempic in a late-stage trial of adults with type 2 diabetes. Retatrutide cut A1C by 2.2% versus 1.8%, and patients lost up to 47.4 pounds versus 20.9 pounds.

Confirmed

Global impact / market context

If approved, retatrutide could take sales from Ozempic by offering doctors a more effective weekly option for diabetes and weight loss. That could shift revenue between Eli Lilly and Novo Nordisk and change how companies plan capital spending on new weight-loss drugs.

Analyst inference

The trial pitted Lilly's triple-G drug, which means it targets three hormone receptors, against Ozempic, the current standard treatment. Stronger results may raise expectations that Lilly can capture more of the weight-loss and diabetes market, pressuring Novo Nordisk's outlook.

Analyst inference

What to watch

1. Lilly said the trial compared 9 mg and 12 mg doses of retatrutide with a 2 mg dose of Ozempic, the highest approved dose, over 80 weeks in adults with type 2 diabetes. Confirmed
2. Lilly's Kenneth Custer said retatrutide, if approved, could shift the treatment paradigm for people with type 2 diabetes, obesity and related cardiometabolic conditions, so regulators may review the full Phase 3 data. Proposed
3. Investors may weigh whether retatrutide's larger weight loss and blood sugar gains translate into doctor prescriptions and insurance coverage, which would drive Lilly revenue and pressure Novo Nordisk's Ozempic sales. Analyst inference

Evidence

• Original source link unavailable